Blood test for Alzheimer's could widen access to early diagnosis

The use of blood biomarker for the diagnosis of Alzheimer's disease It has been gaining attention in scientific research and in the development of new health technologies. Roche recently announced a new blood test designed to help identify biological changes associated with Alzheimer's disease.

The test uses the pTau217 biomarker, a protein associated with the formation of amyloid plaques in the brain, one of the main biological characteristics associated with the disease.

In addition, the technology aims to expand access to less invasive methods to support clinical diagnosis, contributing to faster and more accessible neurological evaluation strategies.

What Is a Blood Biomarker in the Diagnosis of Alzheimer's Disease?

Biomarkers are biological substances that can indicate changes in the body associated with certain diseases.

In the case of Alzheimer's disease, researchers have been investigating biomarkers linked to the accumulation of brain proteins associated with neurodegenerative progression.

Traditionally, tests used to diagnose the disease may include:

• cognitive assessment
• brain imaging tests
• cerebrospinal fluid analysis

However, many of these methods are expensive or require more invasive procedures.

For this reason, advances in blood biomarkers are considered one of the most promising areas in neurology and diagnostic medicine.

How the new blood test works

The test developed by Roche uses the pTau217 biomarker to identify biological markers associated with Alzheimer's-related amyloid pathology.

According to information released by the company, the test has received CE marking in Europe, allowing it to be used in certain European markets.

In addition, the technology is designed to assist healthcare professionals in the diagnostic process, serving as a complementary tool to clinical evaluation.

However, experts emphasize that the test alone does not replace a medical diagnosis, which continues to depend on a comprehensive clinical evaluation and other neurological factors.

Blood Biomarkers in the Diagnosis of Alzheimer's Disease and Precision Medicine

Advances in neurology research are part of a broader trend in modern medicine toward more individualized approaches.

With the growth of precision medicine, researchers have been using biomarkers, artificial intelligence, and data analysis to improve the ability to detect diseases early.

In addition, new diagnostic technologies have been contributing to:

Less invasive methods

Blood tests can reduce the need for more complex procedures at certain stages of a clinical investigation.

Expanding Access to Diagnosis

More affordable technologies can make it easier to conduct tests at different medical centers.

Advances in Clinical Research

Biomarkers also play an important role in the development of clinical trials and targeted therapies.

Innovation in Healthcare and the Future of Diagnostics

Advances in biotechnology and diagnostic medicine continue to expand the possibilities for scientific research in various fields of health.

Furthermore, the use of biomarkers underscores how the integration of technology, science, and clinical research can contribute to more precise and individualized approaches in the future of medicine.

Although many of these technologies are still in the early stages of development, recent advances demonstrate how diagnostic innovation continues to transform the healthcare sector.

If you'd like to learn more about innovation in healthcare and clinical research, be sure to check out other articles published on the FIC Company blog.

👉 See also:

Technology and medicine: how artificial intelligence is expanding the potential of medical tests